Clinical Focus
Business Focus
Spotlight
Subscribe
CE/CME
- Clinical Technology
- Adult Immunization
- Hepatology
- Pediatric Immunization
- Screening
- Psychiatry
- Allergy
- Women's Health
- Cardiology
- Pediatrics
- Dermatology
- Endocrinology
- Pain Management
- Gastroenterology
- Infectious Disease
- Obesity Medicine
- Rheumatology
- Nephrology
- Neurology
- Pulmonology
Survey: Did the FDA Jump the Gun?
Take this MedPage Today survey.
The FDA announced yesterday that studies of two prescription proton-pump inhibitors, omeprazole (Prilosec) and esomeprazole (Nexium), had raised concerns about their cardiovascular safety. In the same announcement, the agency said its preliminary assessment was that the problems seen in those studies were "not a true effect." But a final safety report remained three months away.
Related Videos
Related Content
Phase 3 Data Support Oral Orforglipron for Weight Maintenance After GLP-1–Based Weight Loss
December 19th 2025Article
Topline Phase 3 ATTAIN-MAINTAIN data show oral orforglipron met primary and key secondary endpoints for weight maintenance after prior GLP-1–based injectable therapy in adults with obesity.
